TABLE 2. Estimated vaccination coverage among children aged 19–35 months, by selected vaccines and doses, metropolitan statistical area (MSA) status,* and health insurance status† — National Immunization Survey-Child, United States, 2017§.
| Vaccine/Dose | MSA status
% (95% CI) |
Health insurance status
% (95% CI) |
|||||
|---|---|---|---|---|---|---|---|
| MSA, principal city (referent) (n = 6,689) | MSA, non-principal city (n = 5,846) | Non-MSA (n = 2,798) | Private only (referent) (n = 8,536) | Any Medicaid (n = 5,714) | Other insurance (n = 644) | Uninsured (n = 439) | |
|
DTaP¶
| |||||||
| ≥3 doses |
94.6 (93.4–95.6) |
94.1 (92.9–95.0) |
91.6 (89.1–93.6)** |
96.5 (95.7–97.2) |
92.6 (91.2–93.8)** |
93.7 (90.7–95.8)** |
78.2 (71.3–83.8)** |
| ≥4 doses |
85.0 (83.3–86.5) |
82.6 (80.6–84.5) |
78.1 (74.9–80.9)** |
86.9 (85.2–88.5) |
80.8 (78.9–82.5)** |
83.6 (79.3–87.2) |
62.4 (55.0–69.1)** |
|
Poliovirus (≥3 doses)
|
93.2 (91.9–94.4) |
92.9 (91.7–93.9) |
90.1 (87.4–92.2)** |
95.2 (94.3–96.0) |
91.2 (89.6–92.5)** |
92.7 (89.5–95.0) |
77.9 (71.0–83.6)** |
|
MMR†† (≥1 dose)
|
92.5 (91.2–93.6) |
90.9 (89.3–92.3) |
89.9 (88.0–91.6)** |
93.7 (92.3–94.8) |
90.4 (89.1–91.6)** |
91.0 (87.5–93.6) |
74.6 (67.5–80.6)** |
|
Hib
| |||||||
| Primary series§§ |
93.4 (92.2–94.5) |
92.6 (91.1–93.9) |
91.2 (88.7–93.2) |
95.5 (94.6–96.2) |
91.1 (89.5–92.5)** |
92.2 (88.8–94.7)** |
78.0 (71.1–83.7)** |
| Full series§§ |
81.6 (79.6–83.4) |
80.7 (78.6–82.7) |
77.3 (74.1–80.2)** |
85.1 (83.2–86.9) |
77.7 (75.6–79.7)** |
78.8 (73.8–83.1)** |
62.0 (54.6–68.9)** |
|
HepB
| |||||||
| ≥3 doses |
92.6 (91.3–93.7) |
90.4 (88.7–91.9)** |
90.7 (88.8–92.3) |
93.3 (91.9–94.4) |
90.4 (88.8–91.7)** |
92.5 (89.4–94.7) |
78.6 (71.8–84.1)** |
| Birth dose¶¶ |
73.6 (71.1–76.0) |
72.8 (70.3–75.1) |
76.6 (73.6–79.3) |
73.0 (70.9–75.0) |
74.7 (72.0–77.2) |
71.8 (66.2–76.8) |
68.7 (61.9–74.8) |
|
Varicella†† (≥1 dose)
|
92.3 (91.0–93.4) |
90.4 (88.7–91.8) |
88.3 (86.2–90.1)** |
92.9 (91.5–94.1) |
90.4 (89.1–91.6)** |
91.3 (88.0–93.8) |
69.5 (62.2–76.0)** |
|
PCV
| |||||||
| ≥3 doses |
92.2 (90.5–93.6) |
91.9 (90.4–93.2) |
90.6 (88.0–92.6) |
94.5 (92.9–95.7) |
90.5 (88.9–91.8)** |
91.0 (87.6–93.5)** |
75.2 (67.9–81.2)** |
| ≥4 doses |
83.6 (81.7–85.4) |
82.0 (79.9–84.0) |
79.1 (75.9–81.9)** |
87.6 (85.8–89.3) |
78.9 (76.8–80.8)** |
81.3 (76.8–85.2)** |
59.0 (51.6–66.1)** |
|
HepA
| |||||||
| ≥1 dose |
87.2 (85.3–88.9) |
85.7 (83.9–87.4) |
82.5 (80.1–84.6)** |
88.1 (86.5–89.6) |
85.3 (83.5–87.0)** |
86.1 (81.7–89.5) |
63.3 (55.7–70.3)** |
| ≥2 doses |
61.1 (58.7–63.4) |
59.2 (56.7–61.6) |
56.5 (53.3–59.7)** |
63.2 (61.0–65.2) |
57.7 (55.2–60.2)** |
61.1 (55.2–66.7) |
35.7 (29.1–42.9)** |
|
Rotavirus***
|
73.8 (71.3–76.2) |
73.3 (70.7–75.7) |
70.5 (67.3–73.6) |
81.8 (79.8–83.6) |
66.8 (64.2–69.4)** |
67.4 (61.0–73.3)** |
51.5 (44.2–58.7)** |
|
Combined 7-vaccine series†††
|
71.9 (69.7–74.1) |
69.8 (67.4–72.2) |
66.8 (63.6–69.9)** |
76.0 (73.9–77.9) |
66.5 (64.1–68.9)** |
69.2 (63.6–74.2)** |
48.5 (41.2–55.8)** |
| No vaccinations | 1.0 (0.7–1.3) | 1.1 (0.8–1.5) | 1.9 (1.3–2.7)** | 0.8 (0.6–1.1) | 1.0 (0.7–1.4) | —§§§ | 7.1 (4.6–10.8)** |
Abbreviations: CI = confidence interval; DTaP = diphtheria and tetanus toxoids and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = Haemophilus influenzae type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine.
* MSA status was determined on the basis of household-reported county and city of residence and was grouped into three categories: MSA principal city, MSA nonprincipal city, and non-MSA. MSA and principal city were as defined by the U.S. Census Bureau (https://www.census.gov/geo/reference/gtc/gtc_cbsa.html). Non-MSA areas include urban populations not located within an MSA as well as completely rural areas.
† Children’s health insurance status was reported by parent or guardian. “Other insurance” includes the Children’s Health Insurance Program, military insurance, coverage via the Indian Health Service, and any other type of health insurance not mentioned elsewhere.
§ Children in the 2017 National Immunization Survey-Child were born during January 2014–May 2016.
¶ Includes children who might have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.
** Statistically significant (p<0.05) difference compared with the referent group.
†† Includes children who might have been vaccinated with measles, mumps, rubella, and varicella vaccine.
§§ Hib primary series: ≥2 or ≥3 doses, depending on product type received; full series includes primary series and booster dose, which includes receipt of ≥3 or ≥4 doses, depending on product type received.
¶¶ One dose of HepB administered from birth through age 3 days.
*** Includes ≥2 or ≥3 doses, depending on product type received (≥2 doses for Rotarix [RV1] or ≥3 doses for RotaTeq [RV5]).
††† The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 doses, depending on product type of vaccine), ≥3 doses of HepB, ≥1 dose of varicella, and ≥4 doses of PCV.
§§§ Estimate not available because the 95% CI was ≥20.